Global liver cancer therapeutics market is expected to register a CAGR of 7.54% and reach USD11 billion by 2025. Major factors attributing to the market growth include the growing geriatric population, rising prevalence of chronic diseases, and poor lifestyle choices such as frequent smoking and excessive consumption of alcohol, all of which contribute to liver cancer. Increased investment from both public and private sectors for Research & Development activities in order to find the cure for cancer coupled with the introduction of targeted therapies and vaccines is also likely to propel the demand for the global liver cancer therapeutics market.

Liver cancer is a chronic and life-threatening disease which begins in cells of liver. Most of the liver cancer patients do not show the symptoms at early stages but in advanced stages. Some of the common symptoms include loss of appetite, upper abdominal pain, nausea and vomiting and yellow discoloration of skin. According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe. Another major reason for the increase in the liver cancer is the high increase in the incidences of HBV/HCV coinfection and cirrhosis. Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment. However, the market also faces some restrains. Expensive treatments as well as high investment costs in research and development might hamper further development of liver cancer therapeutics market.

The global liver cancer therapeutics market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region. Based on the route of administration, the market is segmented into oral, intravenous and others. The oral segment is anticipated to dominate the global liver cancer therapeutics market holding a market share of 60.45% by 2025 as it is most preferred route of administration for chemotherapy. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies are anticipated to dominate the market during the forecast period as the drugs are mostly purchased from the hospitals at the time of treatment. Based on therapy the market is segmented into chemotherapy and radiation therapy, immunotherapy, targeted therapy, and others. In 2019, chemotherapy and radiation therapy accounted for the largest market share of 49.83% and the segment is anticipated to dominate the market through 2025.

The onset of COVID-19 has adversely impacted the market on account of significantly lower patient footfall in private clinics and hospital OPDs. Major players operating in the global liver cancer therapeutics market include Bayer AG, Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche AG , Bristol-Myers Squibb Company, Eisai Co., Ltd. , Pfizer Inc., Exelixis, Inc., Merck, Celsion Corporation, Johnson & Johnson, Novartis International AG, Sanofi S.A., Eli Lilly and Company, Perkin Elmer, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., AstraZeneca, Philips Healthcare Pvt. Ltd and others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global liver cancer therapeutics market.
  • To classify and forecast global liver cancer therapeutics market based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • To identify drivers and challenges for global liver cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global liver cancer therapeutics market.
  • To conduct pricing analysis for global liver cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global liver cancer therapeutics market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of leading players operating across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include market players, which could not be identified due to the limitations of secondary research. TechSci Research analyzed the market players, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global liver cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Liver cancer therapeutics players and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to liver cancer therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as market players, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global liver cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Liver Cancer Therapeutics Market, By Cancer Type:
    • Hepatocellular Carcinoma
    • Cholangiocarcinoma
    • Hepatoblastoma
    • Angiosarcoma
    • Liver Metastasis
  • Global Liver Cancer Therapeutics Market, By Therapy:

o   Targeted Therapy

o   Chemotherapy and Radiation Therapy

o   Immunotherapy

o   Others

  • Global Liver Cancer Therapeutics Market, By Equipment:
    • Computed Radiography
    • Sonography
    • MRI
    • Others
  • Market, By Age:
    • 0-18
    • 18-35
    • 35-50
    • 50+
  • Global Liver Cancer Therapeutics Market, By Factors:
    • Cirrhosis
    • Nonalcoholic Fatty Liver Disease
    • Excessive Alcohol Consumption
    • Others
  • Global Liver Cancer Therapeutics Market, By Route of Administration:
    • Oral
    • Intravenous
    • Others

·         Global Liver Cancer Therapeutics Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Liver Cancer Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global liver cancer therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Liver Cancer Therapeutics Market

4.    Voice of Customer

5.    Executive Summary

6.    Global Liver Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, Liver Metastasis)

6.2.2.     By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, Others)

6.2.3.     By Equipment (Computed Radiography, Sonography, MRI, Others)

6.2.4.     By Age (0-18, 18-35, 35-50, 50+)

6.2.5.     By Factors (Cirrhosis, Nonalcoholic Fatty Liver Disease, Excessive Alcohol Consumption, Others)

6.2.6.     By Route of Administration (Oral, Intravenous, Others) 

6.2.7.     By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

6.2.8.     By Company (2019)

6.2.9.     By Region

6.3.  Market Attractiveness Index

7.    Asia-Pacific Liver Cancer Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Cancer Type

7.2.2.     By Therapy

7.2.3.     By Equipment

7.2.4.     By Age

7.2.5.     By Factors

7.2.6.     By Route of Administration

7.2.7.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Liver Cancer Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Cancer Type

7.3.1.2.2.             By Therapy

7.3.1.2.3.             By Equipment

7.3.1.2.4.             By Age

7.3.1.2.5.             By Factors

7.3.1.2.6.             By Route of Administration

7.3.2.     India Liver Cancer Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Cancer Type

7.3.2.2.2.             By Therapy

7.3.2.2.3.             By Equipment

7.3.2.2.4.             By Age

7.3.2.2.5.             By Factors

7.3.2.2.6.             By Route of Administration

7.3.3.     Japan Liver Cancer Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Cancer Type

7.3.3.2.2.             By Therapy

7.3.3.2.3.             By Equipment

7.3.3.2.4.             By Age

7.3.3.2.5.             By Factors

7.3.3.2.6.             By Route of Administration

7.3.4.     South Korea Liver Cancer Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Cancer Type

7.3.4.2.2.             By Therapy

7.3.4.2.3.             By Equipment

7.3.4.2.4.             By Age

7.3.4.2.5.             By Factors

7.3.4.2.6.             By Route of Administration

7.3.5.     Australia Liver Cancer Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Cancer Type

7.3.5.2.2.             By Therapy

7.3.5.2.3.             By Equipment

7.3.5.2.4.             By Age

7.3.5.2.5.             By Factors

7.3.5.2.6.             By Route of Administration

8.    Europe Liver Cancer Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Cancer Type

8.2.2.     By Therapy

8.2.3.     By Equipment

8.2.4.     By Age

8.2.5.     By Factors

8.2.6.     By Route of Administration

8.2.7.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Liver Cancer Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Cancer Type

8.3.1.2.2.             By Therapy

8.3.1.2.3.             By Equipment

8.3.1.2.4.             By Age

8.3.1.2.5.             By Factors

8.3.1.2.6.             By Route of Administration

8.3.2.     Germany Liver Cancer Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Cancer Type

8.3.2.2.2.             By Therapy

8.3.2.2.3.             By Equipment

8.3.2.2.4.             By Age

8.3.2.2.5.             By Factors

8.3.2.2.6.             By Route of Administration

8.3.3.     United Kingdom Liver Cancer Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Cancer Type

8.3.3.2.2.             By Therapy

8.3.3.2.3.             By Equipment

8.3.3.2.4.             By Age

8.3.3.2.5.             By Factors

8.3.3.2.6.             By Route of Administration

8.3.4.     Italy Liver Cancer Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Cancer Type

8.3.4.2.2.             By Therapy

8.3.4.2.3.             By Equipment

8.3.4.2.4.             By Age

8.3.4.2.5.             By Factors

8.3.4.2.6.             By Route of Administration

8.3.5.     Spain Liver Cancer Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Cancer Type

8.3.5.2.2.             By Therapy

8.3.5.2.3.             By Equipment

8.3.5.2.4.             By Age

8.3.5.2.5.             By Factors

8.3.5.2.6.             By Route of Administration

9.    North America Liver Cancer Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Cancer Type

9.2.2.     By Therapy

9.2.3.     By Equipment

9.2.4.     By Age

9.2.5.     By Factors

9.2.6.     By Route of Administration

9.2.7.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Liver Cancer Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Cancer Type

9.3.1.2.2.             By Therapy

9.3.1.2.3.             By Equipment

9.3.1.2.4.             By Age

9.3.1.2.5.             By Factors

9.3.1.2.6.             By Route of Administration

9.3.2.     Mexico Liver Cancer Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Cancer Type

9.3.2.2.2.             By Therapy

9.3.2.2.3.             By Equipment

9.3.2.2.4.             By Age

9.3.2.2.5.             By Factors

9.3.2.2.6.             By Route of Administration

9.3.3.     Canada Liver Cancer Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Cancer Type

9.3.3.2.2.             By Therapy

9.3.3.2.3.             By Equipment

9.3.3.2.4.             By Age

9.3.3.2.5.             By Factors

9.3.3.2.6.             By Route of Administration

10.  South America Liver Cancer Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Cancer Type

10.2.2.  By Therapy

10.2.3.  By Equipment

10.2.4.  By Age

10.2.5.  By Factors

10.2.6.  By Route of Administration

10.2.7.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Liver Cancer Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Cancer Type

10.3.1.2.2.           By Therapy

10.3.1.2.3.           By Equipment

10.3.1.2.4.           By Age

10.3.1.2.5.           By Factors

10.3.1.2.6.           By Route of Administration

10.3.2.  Argentina Liver Cancer Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Cancer Type

10.3.2.2.2.           By Therapy

10.3.2.2.3.           By Equipment

10.3.2.2.4.           By Age

10.3.2.2.5.           By Factors

10.3.2.2.6.           By Route of Administration

10.3.3.  Colombia Liver Cancer Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Cancer Type

10.3.3.2.2.           By Therapy

10.3.3.2.3.           By Equipment

10.3.3.2.4.           By Age

10.3.3.2.5.           By Factors

10.3.3.2.6.           By Route of Administration

11.  Middle East and Africa Liver Cancer Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Cancer Type

11.2.2.  By Therapy

11.2.3.  By Equipment

11.2.4.  By Age

11.2.5.  By Factors

11.2.6.  By Route of Administration

11.2.7.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Liver Cancer Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Cancer Type

11.3.1.2.2.           By Therapy

11.3.1.2.3.           By Equipment

11.3.1.2.4.           By Age

11.3.1.2.5.           By Factors

11.3.1.2.6.           By Route of Administration

11.3.2.  Saudi Arabia Liver Cancer Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Cancer Type

11.3.2.2.2.           By Therapy

11.3.2.2.3.           By Equipment

11.3.2.2.4.           By Age

11.3.2.2.5.           By Factors

11.3.2.2.6.           By Route of Administration

11.3.3.  UAE Liver Cancer Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Cancer Type

11.3.3.2.2.           By Therapy

11.3.3.2.3.           By Equipment

11.3.3.2.4.           By Age

11.3.3.2.5.           By Factors

11.3.3.2.6.           By Route of Administration

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  AbbVie Inc.

14.2.2.  Alnylam Pharmaceuticals Inc.

14.2.3.  Amgen Inc.

14.2.4.  AstraZeneca

14.2.5.  Bayer AG

14.2.6.  Bristol-Myers Squibb Company

14.2.7.  Celsion Corporation

14.2.8.  Eisai Co., Ltd.

14.2.9.  Eli Lilly and Company

14.2.10.                Exelixis, Inc.

14.2.11.            &nb